GlassScriptPhysician profile
Joel M Warren
NPI 1720250749
$13,255.01
in general payments reported to CMS, 2019-2025
45 companies · $3,032 in 2025
The $3,032 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $893 · 2021: $1,346 · 2022: $1,639 · 2023: $2,355 · 2024: $2,955 · 2025: $3,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,216 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,216.29 |
| Education | $125.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,340.81 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,236.92 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $1,156.28 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $980.60 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $818.66 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $428.17 | 2019-2025 | |
| Madrigal Pharmaceuticals | $427.89 | 2025 | Rezdiffra |
| Genzyme Corporation | $421.21 | 2022-2025 | |
| Ardelyx, INC. | $388.49 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $387.03 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $355.26 | 2019-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $329.77 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $276.63 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $263.39 | 2023-2024 | Voquezna |
| Celgene Corporation | $238.74 | 2021-2024 | Zeposia |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $200.66 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Amgen INC. | $182.95 | 2021-2025 | Amjevita, Avsola, Uplizna |
| Organon LLC | $179.03 | 2022-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $169.17 | 2021-2023 | |
| Neuraxis, INC. | $167.09 | 2025 | |
| Braintree Laboratories, INC. | $161.30 | 2022-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $143.84 | 2020-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $141.77 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $134.74 | 2019-2025 | Rebyota |
| Redhill Biopharma INC. | $99.36 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Intercept Pharmaceuticals, INC. | $88.05 | 2019-2025 | |
| Evoke Pharma, INC. | $67.34 | 2021-2023 | Gimoti |
| Alfasigma USA, INC. | $57.02 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $52.25 | 2024-2025 | Zenpep, Vowst |
| Shire North American Group INC | $51.85 | 2019 | |
| Ucb, INC. | $51.57 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $31.71 | 2022 | |
| Medtronic, INC. | $25.74 | 2021 | |
| Pharmacosmos Therapeutics INC. | $23.53 | 2025 | Monoferric |
| Axonics, INC. | $21.93 | 2024 | Axonics |
| Alnylam Pharmaceuticals INC. | $21.38 | 2022 | |
| Akorn, INC. | $20.03 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.01 | 2023 | Austedo Xr |
| Ethicon US, LLC | $16.56 | 2025 | Linx Reflux Management System |
| Allergan, INC. | $16.46 | 2020 | |
| Echosens North America, INC. | $13.24 | 2024 | Fibroscan |
| Olympus America INC. | $13.10 | 2023 | Endoclot Phs |
| Acacia Pharma INC | $12.34 | 2021 | |
| Dova Pharmaceuticals | $11.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.